Drug Topics
OCTOBER 28, 2024
Industry experts gathered to discuss pharmacy benefit managers, their current grasp on the drug supply chain, and how it all impacts independent pharmacies.
STAT
OCTOBER 31, 2024
Teva Pharmaceutical, the world’s largest generic drugmaker, was fined $503 million by European antitrust regulators for delaying competition to a blockbuster multiple sclerosis medicine. The European Commission found the company had artificially extended the patent protection of Copaxone and systematically spread misleading information about a rival product.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
OCTOBER 28, 2024
As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding isn’t enough.
Fierce Pharma
OCTOBER 31, 2024
Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | The FDA this week revised its shortage list to note that the.25 mg starter dose of Novo’s semaglutide-based obesity med Wegovy is now available in the U.S.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
OCTOBER 26, 2024
The Drug Enforcement Administration gives controlled substance licenses, and can just as easily take them away.
STAT
OCTOBER 31, 2024
Two generic drugmakers, Apotex and Heritage Pharmaceuticals, have agreed to pay a combined $49 million to settle allegations they fixed prices on numerous medicines, the first such agreements since state attorneys general began probing price-fixing in the generics industry a decade ago. In 2016, a number of states filed what eventually became the first in a trio of lawsuits against many of the largest generic companies for allegedly coordinating efforts to fix and maintain prices for dozens of m
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Pharma
NOVEMBER 1, 2024
With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semagluti | Novo Nordisk on Friday revealed that its star GLP-1 semaglutide met the mark in a late-stage MASH study. The positive results build on the thesis that GLP-1s could become a foundational piece in the treatment paradigm for the fatty liver disease, according to analysts at William Blair.
Drug Topics
OCTOBER 31, 2024
Researchers conducted a systematic review of randomized trials to determine the efficacy of ketamine for patients with cancer.
STAT
OCTOBER 29, 2024
Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at Mass General Cancer Center. But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta. Shadowed by the successes of other therapies, the field of cancer vaccines was “seemingly dying,” Sullivan said.
PharmaVoice
OCTOBER 30, 2024
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Pharma
OCTOBER 30, 2024
Biopharma production efforts are set to receive a big boost in the U.K. thanks to a new budget rolled out by the Labour Party following this summer’s general election. | As part of the new budget presented Wednesday by the U.K.’s Chancellor of the Exchequer, Rachel Reeves, the country is debuting a new capital grants vehicle known as the Life Sciences Innovative Manufacturing Fund.
Drug Topics
OCTOBER 27, 2024
A second immunization session focused on updates in meningococcal disease, HPV, and Mpox.
STAT
OCTOBER 30, 2024
All doses of Novo Nordisk’s blockbuster diabetes and obesity treatments are listed as available on the Food and Drug Administration’s drug shortage list as of Wednesday, raising the possibility that the medications could soon be taken off the list entirely, a development that could affect compounding pharmacies and patients relying on compounded drugs.
PharmaVoice
NOVEMBER 1, 2024
Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier. But there’s still hope in the pipeline.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
OCTOBER 29, 2024
The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion. The partnership – which has seen a $150 million upfront payment from Novartis alongside a pledge for up to $2.1 billion in milestones – gives the Swiss pharma group rights to Monte Rosa's VAV1-directed molecular glue degrader programme.
Drug Topics
OCTOBER 31, 2024
Presenters at the National Community Pharmacists Association 2024 Annual Convention and Expo discussed workflow and the future of pharmacy as a patient destination.
STAT
OCTOBER 29, 2024
Sen. Elizabeth Warren (D-Mass.) is urging the Federal Trade Commission to scrutinize recent deals from McKesson and Cardinal Health to buy oncology practices, saying those transactions pose “clear, anticompetitive risks.” McKesson, Cardinal Health, and Cencora are the three dominant wholesalers that distribute drugs and medical products.
PharmaVoice
OCTOBER 31, 2024
Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
NOVEMBER 1, 2024
ASHP investigators determined the severity and impact of ongoing drug shortages, with approximately 99% of respondents reporting that they experienced a shortage.
Drug Topics
OCTOBER 27, 2024
PBM reform legislation has progressed further in Congress than ever before.
STAT
OCTOBER 28, 2024
A drug used to combat fungal infections in cancer patients comes with a big caveat — research shows the medicine can last twice as long as in people with obesity. This means chemotherapies may be less effective when interacting with the medicine, but some clinicians, and their patients, are unaware of that possibility. The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population.
OctariusRx
OCTOBER 28, 2024
Speaking at the “2024 Northeast ASC Conference” is always a great time. A special thank you to MAASC President, Greg DeConciliis for the invitation to participate. My presentation focused on current topics in medication management, including patient safety, safe injection practices and controlled substances. As always, the most rewarding part of the conference was seeing old friends and meeting new ones.
Fierce Pharma
OCTOBER 29, 2024
After the recent FDA approval for the promising schizophrenia drug Cobenfy (xanomeline and trospium chloride), Bristol Myers Squibb and its partners are moving fast to expand the global reach of th | In a phase 3 bridging study run by Zai Lab in China, Bristol Myers Squibb's KarXT helped schizophrenia patients chart a 9.2-point total-score reduction on the Positive and Negative Syndrome Scale versus placebo at week 5, teeing up a forthcoming regulatory filing.
Drug Topics
OCTOBER 27, 2024
A conversation with Lauren Angelo, PharmD, MBA, associate dean of academic affairs and associate professor of pharmacy practice at Rosalind Franklin University of Medicine and Science College of Pharmacy.
STAT
OCTOBER 29, 2024
As Chinese biopharma companies rise on the international stage, they are increasingly finding VC partners — in the United States. U.S. companies have long signed licensing deals with Chinese drugmakers. But increasingly American venture capitalists are building U.S.-based companies from scratch to test and ultimately seek to commercialize innovative drugs developed in China.
Pharmacy Times
OCTOBER 29, 2024
The STRIPE Double Helix Awards celebrate individuals and organizations that have made exceptional contributions to the field of pharmacogenomics.
Pharmafile
OCTOBER 29, 2024
Chiesi Global Rare Diseases have announced the results from their BRIGHT trial, which evaluates the efficacy of enzyme-replacement therapy drug ELFABRIO at twice the approved dose in patients who have been treated with agalsidase alfa or beta. The current approved dose of pegunigalside alfa-iwxj (ELFABRIO) is 1miligramg (mg) per kilogram (kg) administered every two weeks. […] The post Chiesi announces phase 3 results from enzyme-replacement study appeared first on Pharmafile.
Drug Topics
OCTOBER 29, 2024
The addition of a 10 mg oxycodone hydrochloride tablet improves dosing flexibility and precision.
STAT
OCTOBER 29, 2024
The historic Inflation Reduction Act of 2022 has fundamentally improved the affordability of and access to prescription drugs for millions of people with Medicare. The law laid out aggressive timelines for implementing the Medicare Drug Price Negotiation Program. As the director of Medicare, my team and I worked thoughtfully and diligently to stand up the program — on time and successfully.
Pharmacy Times
OCTOBER 26, 2024
Changing the way pharmacists and pharmacy staff think about themselves is key, although providers, payers, and patients must also change how they view the value of pharmacy services.
PharmaVoice
OCTOBER 29, 2024
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.
Drug Topics
OCTOBER 30, 2024
Cassandra Esperant, PharmD, AAHIVP, leverages her skills as a clinical pharmacist to champion the health of patients with HIV, both in her clinical practice and through education initiatives.
STAT
OCTOBER 27, 2024
Here’s the paradox: The most influential set of rules for the foods we eat are the ones most of us ignore. But they still matter for millions of Americans. The Dietary Guidelines for Americans, reviewed and issued by the federal government every five years, have broad impact on what goes into federal nutritional assistance programs, from WIC for women and young children to school lunches to meals for veterans or seniors.
Expert insights. Personalized for you.
551 
Let's personalize your content